Esperion to Participate in Upcoming June Investor Conferences
Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.
The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025: la Jefferies Global Healthcare Conference a New York il 4 giugno alle 13:25 ET e la Goldman Sachs Global Healthcare Conference a Miami il 9 giugno alle 10:40 ET.
L'azienda, una societ脿 biofarmaceutica in fase commerciale, 猫 specializzata in farmaci orali approvati dalla FDA, da assumere una volta al giorno, non statine, destinati a pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dallo studio CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti. Esperion sta inoltre sviluppando inibitori di nuova generazione dell'ATP citrato liasi (ACLYi) e sta espandendo la propria presenza a livello globale attraverso l'esecuzione commerciale e partnership internazionali.
Esperion (NASDAQ: ESPR) ha anunciado su participaci贸n en dos importantes conferencias para inversores en junio de 2025: la Jefferies Global Healthcare Conference en Nueva York el 4 de junio a la 1:25 p.m. ET, y la Goldman Sachs Global Healthcare Conference en Miami el 9 de junio a las 10:40 a.m. ET.
La compa帽铆a, una firma biofarmac茅utica en etapa comercial, se especializa en medicamentos orales aprobados por la FDA, de una vez al d铆a, no estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos est谩n respaldados por el ensayo CLEAR Cardiovascular Outcomes Trial, que involucr贸 a casi 14,000 pacientes. Esperion tambi茅n est谩 desarrollando inhibidores de la ATP citrato liasa (ACLYi) de pr贸xima generaci贸n y expandi茅ndose globalmente a trav茅s de la ejecuci贸n comercial y asociaciones internacionales.
鞐愳姢韼橂Μ鞓� (NASDAQ: ESPR)鞚� 2025雲� 6鞗� 霊� 臧滌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟: 6鞗� 4鞚� 雺挫殨鞐愳劀 鞐措Μ電� Jefferies Global Healthcare Conference 鞓ろ泟 1鞁� 25攵�(霃欕秬鞁滉皠), 攴鸽Μ瓿� 6鞗� 9鞚� 毵堨澊鞎犽鞐愳劀 鞐措Μ電� Goldman Sachs Global Healthcare Conference 鞓れ爠 10鞁� 40攵�(霃欕秬鞁滉皠)鞛呺媹雼�.
鞚� 須岇偓電� 靸侅梾 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 鞁槇甏� 歆堩櫂瓿� 雴掛潃 LDL-C 靾橃箻毳� 臧�歆� 頇橃瀽霌れ潉 鞙勴暅 FDA 鞀轨澑 甑皶鞖� 牍勳姢韮�韹挫牅(頃橂（ 1須� 氤奠毄)毳� 鞝勲鞙茧 頃╇媹雼�. 鞚措摛鞚� 鞎诫鞚� 鞎� 14,000氇呾潣 頇橃瀽臧� 彀胳棳頃� CLEAR 鞁槇甏� 瓴瓣臣 鞁滍棙鞐� 鞚橅暣 霋冯皼旃惄雼堧嫟. 鞐愳姢韼橂Μ鞓潃 霕愴暅 彀劯雽� ATP 鞁滍姼毳挫偘 攵勴暣須唽 鞏奠牅鞝�(ACLYi)毳� 臧滊皽 欷戩澊氅�, 靸侅梾鞝� 鞁ろ枆瓿� 甑牅 韺岉姼雱堨嫮鞚� 韱淀暣 旮�搿滊矊 頇曥灔鞚� 於旍頃橁碃 鞛堨姷雼堧嫟.
Esperion (NASDAQ : ESPR) a annonc茅 sa participation 脿 deux grandes conf茅rences pour investisseurs en juin 2025 : la Jefferies Global Healthcare Conference 脿 New York le 4 juin 脿 13h25 ET, et la Goldman Sachs Global Healthcare Conference 脿 Miami le 9 juin 脿 10h40 ET.
La soci茅t茅, une entreprise biopharmaceutique en phase commerciale, se sp茅cialise dans les m茅dicaments oraux non-statines approuv茅s par la FDA, 脿 prise quotidienne unique, destin茅s aux patients atteints de maladies cardiovasculaires et pr茅sentant un taux 茅lev茅 de LDL-C. Leurs m茅dicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes Trial impliquant pr猫s de 14 000 patients. Esperion d茅veloppe 茅galement des inhibiteurs de nouvelle g茅n茅ration de l'ATP citrate lyase (ACLYi) et 茅tend sa pr茅sence mondiale gr芒ce 脿 une ex茅cution commerciale et des partenariats internationaux.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angek眉ndigt: der Jefferies Global Healthcare Conference in New York am 4. Juni um 13:25 Uhr ET und der Goldman Sachs Global Healthcare Conference in Miami am 9. Juni um 10:40 Uhr ET.
Das Unternehmen, ein biopharmazeutisches Unternehmen in der kommerziellen Phase, spezialisiert sich auf von der FDA zugelassene orale, einmal t盲glich einzunehmende Nicht-Statin-Medikamente f眉r Patienten mit Herz-Kreislauf-Erkrankungen und erh枚htem LDL-C. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Trial gest眉tzt, an der fast 14.000 Patienten teilnahmen. Esperion entwickelt au脽erdem die n盲chste Generation von ATP-Citrat-Lyase-Inhibitoren (ACLYi) und expandiert global durch kommerzielle Umsetzung und internationale Partnerschaften.
- None.
- None.
ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations .
Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET.
Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET.
Live webcasts can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company鈥檚 website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on and .
Esperion Contact Information:听
Investors:听听
Alina Venezia听
(734) 887-3903听
Media:听听
Tiffany Aldrich听听
(616) 443-8438听
FAQ
What investor conferences will Esperion (ESPR) attend in June 2025?
How can investors access Esperion's (ESPR) conference presentations?
What are Esperion's (ESPR) main pharmaceutical products?
What is Esperion's (ESPR) next-generation drug development program?
